MDR-TB management: what is new? Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012
MDR-TB guidelines: what is new on clinical management Source: ERS Webinar 2020: MDR-TB guidelines: what is new on clinical management Year: 2020
Our experience and treatment results of multidrug-resistant tuberculosis (MDR-TB) patients between 1996-2002 Source: Eur Respir J 2003; 22: Suppl. 45, 42s Year: 2003
Treatment outcomes and deaths among multidrug-resistant tuberculosis (MDR-TB) patients in Gomel region, Belarus – 2009-2010 Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Indicators of rifampicin-resistant TB response in Belarus, 2009-2014 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Trend and risk factors of drug resistance tuberculosis between 2005-2012 in Istanbul, Turkey Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Treatment of multidrug-resistant tuberculosis in Uzbekistan from 2012 to 2018: does practice follow policy? Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
Why did they get XDR TB ? Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Treatment outcomes of smear-positive pulmonary TB cases in Romania in 2006-2008 Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010
First national survey results of mycobacterium tuberculosis drug resistance in Kosovo, 2007-2008 Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011
The top of the iceberg - Extensively drug resistant tuberculosis (XDR-TB) in 2010 Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children Year: 2015
MDR-TB treatment outcomes in HIV positive patients Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014
The global risk of dying from multidrug-resistant tuberculosis (MDR-TB) Source: International Congress 2014 – Tuberculosis epidemiology: novel features Year: 2014
The twin epidemics: HIV / DR-TB co-infection in 2012 Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children Year: 2015
Predisposing factors of multi drug resistant tuberculosis (MDR-TB) in Sardjito Hospital, Yogyakarta, Indonesia in 2009-2012 Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014
Characteristics of XDR-TB patients in Israel: 2000-2010 Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011
Active pharmacovigilance for multidrug-resistant tuberculosis patients treated with Linezolid, Belarus – 2014-2015 Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
HIV testing in new patients with TB: attitudes and action in the U.K. in 2006 Source: Annual Congress 2007 - Tuberculosis control Year: 2007
Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016